Research and Development

Compare to small molecule drugs, biologics are superior in clinical treatment due to their higher specificity and lower side effects. In recent years, monoclonal antibody drug is considered to have the most potential and has become the driving force in the rapid developing biologics market. Seven out of top 10 biopharmaceuticals in 2019 were monoclonal antibody drugs with total revenue of $6472.3 million USD. 

Antibody is a Y-shaped molecule about 150 kd in size. The Fab region is where the antibody binds to antigen, and the Fc region decides antibody effector function. Most available antibody drugs on the market are IgG1, and the Asn297 of the Fc region of IgG1 is often modified by glycan, which display very heterogeneous structures. Actually, the structure of this glycan changes with expression system. Therefore, most antibody drugs on the market are mainly manufactured using CHO cells, which can produce glycans with the structure most similar to glycan structure from human, to avoid undesired side-effects. Moreover, because the structure of glycan on the antibody is related to the antibody effector function, major pharmaceutical companies have been devoting manpower and resources into improving monoclonal antibody efficacy through glycan structure modification. Subsequently, many glycoengineered antibody drugs, such as Poteligeo, Gazyva, Fasenra, and Blenrep, were approved by FDA between 2012 and 2020. The prospect of monoclonal antibody drugs is recognized and approved by the market.However, the antibody drugs made by these glyco-engineering technologies mainly increase the Antibody Dependent Cell-mediated Cytotoxicity (ADCC) of the antibody. The figure below shows that the structure of glycans on the the antibody Fc region can be different from various types. The activated or inhibitory Fc receptor binding on immune cells affects the activation or inhibitory effect of the immune cells. Therefore, the structure of the glycan on the antibody Fc region is not only affected ADCC. The key technology of CHO PHARMA INC., “CHOptimaxTM” will be the best tool for understanding and regulating the function of antibodies and immune cells. It is also the unique technology of CHO PHARMA INC., leading the world.



Different from other glycoengineering technology that increases antibody efficacy by modifying glycogenes of production cell line in-vivo, CHO Pharma Inc. has developed a revolutionary glycochemical engineering technology platform, CHOptimaxTM, to improve antibody efficacy. Comparison of the methods is illustrated in the table:



In short, CHOptimaxTM can develop homogenous antibody drugs that have higher efficacy, lower side-effect, and specific CMC. CHOptimaxTM can rapidly produce specific human homogenous antibody drugs containing the fully human glycan structure, particularly the two 2-6 sialic acids in the terminal site of glycan structure, which cannot be produced by any other available glycoengineering technology.

Since its founding, CHO Pharma Inc. has been translating exclusive authorization of academic research results, such as glycoprotein, carbohydrate-based vaccine, glycan microarray, and glyco-probe, from Academia Sinica into industrial development technology. Moreover, the company has been focusing on improving the innovative platform technology, laying out global patent scheme, developing glycan related technology platform to ultimately develop new generation of antibody drugs. Furthermore, we will continue to dedicate appropriate resource for exploratory research in cancers and autoimmune diseases to improve treatment efficacy and extend the pipeline. Finally, we will continue to secure patents in glycan, enzyme, and production process to ensure our global leadership.